Stephen Hoge Sells 341 Shares of Moderna, Inc. (NASDAQ:MRNA) Stock

Moderna, Inc. (NASDAQ:MRNAGet Free Report) President Stephen Hoge sold 341 shares of the company’s stock in a transaction dated Wednesday, May 29th. The stock was sold at an average price of $144.50, for a total value of $49,274.50. Following the completion of the sale, the president now owns 1,471,777 shares of the company’s stock, valued at approximately $212,671,776.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Stephen Hoge also recently made the following trade(s):

  • On Friday, May 10th, Stephen Hoge sold 255 shares of Moderna stock. The stock was sold at an average price of $120.96, for a total value of $30,844.80.
  • On Monday, April 15th, Stephen Hoge sold 15,000 shares of Moderna stock. The stock was sold at an average price of $105.02, for a total value of $1,575,300.00.

Moderna Stock Down 5.9 %

Moderna stock opened at $142.55 on Friday. The company has a debt-to-equity ratio of 0.04, a current ratio of 4.03 and a quick ratio of 3.91. The stock has a market capitalization of $54.63 billion, a price-to-earnings ratio of -9.10 and a beta of 1.57. Moderna, Inc. has a 1-year low of $62.55 and a 1-year high of $170.47. The business has a fifty day moving average price of $120.42 and a 200-day moving average price of $103.21.

Moderna (NASDAQ:MRNAGet Free Report) last issued its quarterly earnings results on Thursday, May 2nd. The company reported ($3.07) EPS for the quarter, topping analysts’ consensus estimates of ($3.59) by $0.52. Moderna had a negative return on equity of 20.10% and a negative net margin of 115.82%. The company had revenue of $167.00 million during the quarter, compared to analysts’ expectations of $93.26 million. During the same quarter in the previous year, the firm posted $0.19 EPS. The firm’s revenue was down 91.0% compared to the same quarter last year. Equities research analysts forecast that Moderna, Inc. will post -7.47 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have commented on MRNA. UBS Group raised their price objective on Moderna from $143.00 to $151.00 and gave the stock a “buy” rating in a report on Tuesday, May 7th. Jefferies Financial Group restated a “buy” rating and set a $125.00 price objective on shares of Moderna in a report on Tuesday, April 9th. Evercore ISI assumed coverage on Moderna in a report on Tuesday, May 14th. They issued an “in-line” rating and a $120.00 price target on the stock. HSBC reiterated a “reduce” rating and issued a $86.00 price target (up from $75.00) on shares of Moderna in a report on Monday, February 26th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Moderna in a report on Thursday, May 2nd. Two analysts have rated the stock with a sell rating, nine have assigned a hold rating and six have given a buy rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $126.46.

Read Our Latest Stock Report on MRNA

Institutional Trading of Moderna

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Cedar Wealth Management LLC lifted its position in Moderna by 45.0% during the 1st quarter. Cedar Wealth Management LLC now owns 290 shares of the company’s stock worth $31,000 after acquiring an additional 90 shares during the period. Allworth Financial LP lifted its holdings in shares of Moderna by 6.5% in the 4th quarter. Allworth Financial LP now owns 1,660 shares of the company’s stock valued at $165,000 after buying an additional 101 shares during the period. TIAA Trust National Association lifted its holdings in shares of Moderna by 2.3% in the 4th quarter. TIAA Trust National Association now owns 4,491 shares of the company’s stock valued at $447,000 after buying an additional 102 shares during the period. Principle Wealth Partners LLC lifted its holdings in shares of Moderna by 4.3% in the 1st quarter. Principle Wealth Partners LLC now owns 2,497 shares of the company’s stock valued at $266,000 after buying an additional 102 shares during the period. Finally, Sound Income Strategies LLC lifted its holdings in shares of Moderna by 17.8% in the 4th quarter. Sound Income Strategies LLC now owns 762 shares of the company’s stock valued at $76,000 after buying an additional 115 shares during the period. Institutional investors and hedge funds own 75.33% of the company’s stock.

About Moderna

(Get Free Report)

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.

Featured Stories

Insider Buying and Selling by Quarter for Moderna (NASDAQ:MRNA)

Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.